摘要
华法林是目前临床上应用最广泛的口服抗凝药,其治疗安全范围窄,剂量个体差异大,临床应用中容易出现抗凝不当所致的并发症。近3年来,随着药物基因组学的快速发展,发现细胞色素P450酶4F2(CYP4F2)基因多态性(rs2108622)与华法林个体剂量差异相关。本文综述了近3年来在不同人种中进行的有关CYP4F2*3(rs2108622)与华法林的维持剂量关系的研究。大多数研究发现CYP4F2基因多态性与华法林维持剂量存在相关性,其中突变的T等位基因与华法林高剂量相关;CYP4F2*3可以解释1%~10%华法林剂量个体差异。
Currently,warfarin is the most widely used oral anticoagulant in clinic.Since warfarin has narrow therapeutic window and significant individual differences in dose,it easily leads to complications due to improper anticoagulate therapy.In recent 3 years,as the rapid development of pharmacogenomics,it has been found that CYP4F2(cytochrome P450,family 4,subfamily F,polypeptide 2) gene polymorphism(rs2108622) relates to warfarin individual dosage requirement.We reviewed research progress in association between CYP4F2 gene polymorphism.Most studies found that CYP4F2 gene polymorphism relates to warfarin dose,and the mutant T allele was associated with higher warfarin dose requirement,CYP4F2*3 polymorphism can explain 1%~10% warfarin individual dosage difference.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2011年第13期1183-1187,共5页
Chinese Journal of New Drugs